Literature DB >> 8812248

Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice.

P C Chan1, R C Sills, A G Braun, J K Haseman, J R Bucher.   

Abstract

delta 9-Tetrahydrocannabinol (delta 9-THC) was studied for potential carcinogenicity in rodents because it is the principal psychoactive ingredient in marihuana and it has potential medicinal uses. delta 9-THC in corn oil was administered by gavage to groups of male and female Fischer rats and B6C3F1 mice at 0, 5, 15, 50, 150, or 500 mg/kg, 5 days a week for 13 weeks and for 13-week plus a 9-week recovery period, and to groups of rats at 0, 12.5, or 50 mg/kg and mice at 0, 125, 250, or 500 mg/kg, 5 times a week for 2 years. In all studies, mean body weights of dosed male and female rats and mice were lower than controls but feed consumptions were similar. Convulsions and hyperactivity were observed in dosed rats and mice; the onset and frequency were dose related. Serum FSH and LH levels in all dosed male rats and corticosterone levels in 25 mg/kg female rats were significantly higher than controls at 15 months in the 2-year studies. delta 9-THC administration for 13 weeks induced testicular atrophy and uterine and ovarian hypoplasia; the lesions persisted in a 9-week recovery period. In the 2-year studies, survival of dosed rats was higher than controls; that of mice was similar to controls. Incidences of testicular interstitial cell, pancreas and pituitary gland adenomas in male rats, mammary gland fibroadenoma and uterus stromal polyp in female rats, and hepatocellular adenoma/carcinoma in male and female mice were reduced in a dose-related manner. Decreased tumor incidences may be at least in part due to reduced body weights of dosed animals. Incidences of thyroid gland follicular cell hyperplasia were increased in all dosed groups of male and female mice, and follicular cell adenomas were significantly increased in the 125 mg/kg group of males, but there was no evidence of a dose-related trend in proliferative lesions of the thyroid. There was no evidence that delta 9-THC was carcinogenic in rats or mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8812248     DOI: 10.1006/faat.1996.0048

Source DB:  PubMed          Journal:  Fundam Appl Toxicol        ISSN: 0272-0590


  18 in total

1.  Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.

Authors:  Catherine Lombard; Venkatesh L Hegde; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2011-08-10       Impact factor: 4.030

2.  Interactions between cannabidiol and Δ9 -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome.

Authors:  Lyndsey L Anderson; Ivan K Low; Iain S McGregor; Jonathon C Arnold
Journal:  Br J Pharmacol       Date:  2020-07-27       Impact factor: 8.739

Review 3.  Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.

Authors:  Evan C Rosenberg; Pabitra H Patra; Benjamin J Whalley
Journal:  Epilepsy Behav       Date:  2017-02-09       Impact factor: 2.937

4.  Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model.

Authors:  Rupal Pandey; Venkatesh L Hegde; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2011-06-14       Impact factor: 4.030

Review 5.  Cannabinoids and cancer: pros and cons of an antitumour strategy.

Authors:  Maurizio Bifulco; Chiara Laezza; Simona Pisanti; Patrizia Gazzerro
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

6.  Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties.

Authors:  Venkatesh L Hegde; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

Review 7.  Towards the use of cannabinoids as antitumour agents.

Authors:  Guillermo Velasco; Cristina Sánchez; Manuel Guzmán
Journal:  Nat Rev Cancer       Date:  2012-05-04       Impact factor: 60.716

8.  Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.

Authors:  Venkatesh L Hegde; Shweta Hegde; Benjamin F Cravatt; Lorne J Hofseth; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Mol Pharmacol       Date:  2008-04-03       Impact factor: 4.436

Review 9.  Marijuana: respiratory tract effects.

Authors:  Kelly P Owen; Mark E Sutter; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

Review 10.  The analgesic potential of cannabinoids.

Authors:  Jaseena Elikkottil; Jaseena Elikottil; Pankaj Gupta; Kalpna Gupta
Journal:  J Opioid Manag       Date:  2009 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.